

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Review Proposal Project

NICE Technology Appraisal No.335; Rivaroxaban for the prevention of adverse outcomes in patients after the acute management of acute coronary syndrome

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company/sponsor</u></p> <ul style="list-style-type: none"> • Bayer <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Anticoagulation UK • Blood Pressure UK (formerly Blood Pressure Association) • British Cardiac Patients Association • Cardiac Risk in the Young • Cardiovascular Care Partnership • Circulation Foundation • Coronary Prevention Group • HEART UK • Muslim Council of Britain • Network of Sikh Organisations • Pumping Marvellous Foundation • Somerville Foundation • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • British Association for Nursing in Cardiovascular Care • British Atherosclerosis Society • British Cardiovascular Society • British Geriatrics Society • British Heart Foundation • British Hypertension Society • British Nuclear Cardiology Society • British Society for Haematology • British Society for Haemostasis and Thrombosis • British Thoracic Society 	<p><u>General commentators</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee • All Wales Therapeutics and Toxicology Centre <p><u>Comparators</u></p> <ul style="list-style-type: none"> • Accord Healthcare (clopidogrel) • Alliance Pharmaceuticals (aspirin) • Actavis UK (clopidogrel, aspirin) • Aurobindo Pharma (clopidogrel) • Concordia International (aspirin) • Consilient Health (clopidogrel) • Dexcel Pharma (aspirin) • GlaxoSmithKline Consumer Healthcare (aspirin) • Intraparm Laboratories (aspirin) • Pfizer Consumer Healthcare (aspirin) • Reckitt Benckiser Healthcare (aspirin)

NICE Technology Appraisal No. 335; Rivaroxaban for the prevention of adverse outcomes in patients after the acute management of acute coronary syndrome

Issue date: May 2018

© NICE 2018. All rights reserved. [Subject to Notice of rights.](#)

<ul style="list-style-type: none"> • Clinical Leaders of Thrombosis (CLOT) • National Heart Forum • Primary Care Cardiovascular Society • Royal College of Emergency Medicine • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for Cardiological Science and Technology • Society for Vascular Nurses • Society for Vascular Technology • UK Clinical Pharmacy Association • UK Health Forum (formerly National Heart Forum (UK)) • Vascular Society of Great Britain and Ireland <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS England • NHS Hammersmith and Fulham CCG • NHS South Norfolk CCG • Welsh Government 	<ul style="list-style-type: none"> • Sandoz (clopidogrel) • Sanofi (clopidogrel) • Zentiva (clopidogrel) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Society for Cardiovascular Research [BCS affiliated] • Cardiac and Cardiology Research Dept, Barts • Central Cardiac Audit Database • Cochrane Heart Group • Cochrane Hypertension Group • Cochrane Stroke Group • CODA • European Council for Cardiovascular Research • MRC Clinical Trials Unit • National Centre for Cardiovascular Preventions and Outcomes • National Institute for Health Research • Wellcome Trust <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales
---	--

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

MTA Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to prepare a submission dossier, can respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non- company consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company organisations can nominate clinical or patient experts to present their personal views to the Appraisal Committee.